N
PRTK

Nuveen’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Nuveen’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-133,751
Closed -$425K – 3565
2022
Q1 		$425K Buy
133,751
+1,002
+0.8% +$3.77K ﹤0.01% 3059
2021
Q4 		$564K Sell
132,749
-18,652
-12% -$88.5K ﹤0.01% 3047
2021
Q3 		$727K Buy
151,401
+2,858
+2% +$15.8K ﹤0.01% 3093
2021
Q2 		$1.01M Sell
148,543
-10,342
-7% -$83.6K ﹤0.01% 2999
2021
Q1 		$1.12M Sell
158,885
-6,388
-4% -$46K ﹤0.01% 2851
2020
Q4 		$1.03M Sell
165,273
-20,987
-11% -$124K ﹤0.01% 2794
2020
Q3 		$1.01M Buy
186,260
+60,025
+48% +$297K ﹤0.01% 2691
2020
Q2 		$659K Sell
126,235
-67,222
-35% -$299K ﹤0.01% 2795
2020
Q1 		$610K Buy
193,457
+87,258
+82% +$322K ﹤0.01% 2704
2019
Q4 		$428K Sell
106,199
-14,675
-12% -$50.9K ﹤0.01% 2941
2019
Q3 		$522K Sell
120,874
-7,338
-6% -$29.3K ﹤0.01% 2935
2019
Q2 		$512K Buy
+128,212
New +$610K ﹤0.01% 3001

Other funds holding PRTK

ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
GAI
General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BC
Bruce & Co Chicago, Illinois $350M AUM 33.5% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FIG
Fortress Investment Group New York $394M AUM 22.99% 1-Year Est. Return

Nuveen's PRTK Position: Q2 2022 in Review

Nuveen sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q2 2022, closing a stake of 133,751 shares — an estimated $425K sold.

Nuveen first reported a position in PRTK in Q2 2019 and held it in 12 quarters. The position peaked at $1.12M in Q1 2021. 84 funds tracked by Wall St. Rank hold PRTK as of Q2 2022.

  • Nuveen reported no remaining Paratek Pharmaceuticals, Inc. position as of Q2 2022 after selling out during the quarter.
  • Nuveen sold 133,751 Paratek Pharmaceuticals, Inc. shares in Q2 2022, an estimated $425K.
  • Nuveen first reported a position in Paratek Pharmaceuticals, Inc. in Q2 2019 and held it in 12 quarters.
  • Nuveen's Paratek Pharmaceuticals, Inc. position peaked at $1.12M in Q1 2021.
  • 84 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q2 2022.

Based on Nuveen's 13F filing for Q2 2022, filed 15 Aug 2022.